CalciMedica (CALC) Set to Release Earnings on Wednesday

CalciMedica (NASDAQ:CALC – Get Free Report) is projected to release its resultson Wednesday, November 11th. Analysts expect CalciMedica to post earnings of ($1.2750) per share for the quarter.

CalciMedica (NASDAQ:CALC – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.97. On average, analysts expect CalciMedica to post ($5.25) EPS for the current fiscal year and ($3.15) EPS for the next fiscal year.

CalciMedica Stock Up 11.4%

CALC stock opened at $1.51 on Tuesday. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. The stock has a market capitalization of $10.35 million, a price-to-earnings ratio of -0.22 and a beta of 0.84. The business’s fifty day moving average price is $1.60 and its two-hundred day moving average price is $3.50. CalciMedica has a fifty-two week low of $1.00 and a fifty-two week high of $36.00.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CALC shares. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Wall Street Zen lowered shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. Weiss Ratings upgraded shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Guggenheim began coverage on shares of CalciMedica in a research note on Thursday, August 20th. They issued a “buy” rating for the company. Finally, UBS Group reissued a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $50.00.

View Our Latest Analysis on CalciMedica

CalciMedica Company Profile

(Get Free Report)

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.

Read More

Earnings History for CalciMedica (NASDAQ:CALC)

Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.